Literature DB >> 11079644

Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans.

A Prasad1, S Husain, W Schenke, R Mincemoyer, N Epstein, A A Quyyumi.   

Abstract

OBJECTIVES: The aim of our study was to investigate coronary vascular kinin receptor function in patients with atherosclerosis or its risk factors.
BACKGROUND: Although acetylcholine (ACH) is used as a probe for testing vascular function in vivo, endogenous bradykinin (BK) regulates resting and flow-mediated epicardial tone.
METHODS: In 53 patients with mild atherosclerosis or its risk factors and 9 control subjects, endothelium-dependent vasomotion was tested with intracoronary ACH (30 microg/min) and BK (62.5 ng/min and 4 microg/min), and endothelium-independent function with sodium nitroprusside. Metabolic vasodilation was assessed during cardiac pacing (n = 19). Correlation with serum angiotensin-converting enzyme (ACE) levels and the ACE insertion/deletion genotype was performed.
RESULTS: There was progressive impairment in ACH-mediated microvascular dilation with increasing numbers of risk factors (p = 0.025, analysis of variance). By contrast, BK- and sodium nitroprusside-mediated microvascular dilation was similar in all groups. Similarly, there was no correlation between epicardial coronary responses to ACH and BK; segments that constricted or dilated with ACH had similar dilator responses with BK. Bradykinin, but not ACH-mediated vasomotion, was depressed in epicardial segments that constricted with pacing. Finally, epicardial BK responses were depressed in patients with high ACE levels and in those with the ACE DD genotype.
CONCLUSIONS: Endothelial dysfunction in atherosclerosis appears to be receptor-specific, involving the muscarinic receptor with relative sparing of the kinin receptor pathways. Abnormal reactivity of epicardial coronary arteries during physiologic stress is better represented by BK and not by ACH responses. Bradykinin activity and, hence, physiologic coronary vasomotion appears to be influenced by serum ACE levels and the ACE insertion/deletion genotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079644     DOI: 10.1016/s0735-1097(00)00892-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS.

Authors:  Hubert Dabiré; Inès Barthélémy; Nicolas Blanchard-Gutton; Lucien Sambin; Carolina Carlos Sampedrano; Vassiliki Gouni; Yves Unterfinger; Pablo Aguilar; Jean-Laurent Thibaud; Bijan Ghaleh; Alain Bizé; Jean-Louis Pouchelon; Stéphane Blot; Alain Berdeaux; Luc Hittinger; Valérie Chetboul; Jin Bo Su
Journal:  Basic Res Cardiol       Date:  2011-12-23       Impact factor: 17.165

2.  Peripheral Microvascular Function Reflects Coronary Vascular Function.

Authors:  Ahmed Al-Badri; Jeong Hwan Kim; Chang Liu; Puja K Mehta; Arshed A Quyyumi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04-25       Impact factor: 8.311

3.  Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Authors:  T Heare; N J Alp; D A Priestman; A B Kulkarni; P Qasba; T D Butters; R A Dwek; K Clarke; K M Channon; F M Platt
Journal:  J Inherit Metab Dis       Date:  2006-12-25       Impact factor: 4.982

4.  The Relationship of Metabolic Syndrome with Stress, Coronary Heart Disease and Pulmonary Function--An Occupational Cohort-Based Study.

Authors:  Miroslaw Janczura; Grazyna Bochenek; Roman Nowobilski; Jerzy Dropinski; Katarzyna Kotula-Horowitz; Bartosz Laskowicz; Andrzej Stanisz; Jacek Lelakowski; Teresa Domagala
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

5.  Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease.

Authors:  Leanid Luksha; Peter Stenvinkel; Folke Hammarqvist; Juan Jesús Carrero; Sandra T Davidge; Karolina Kublickiene
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.